GHRS Stock Forecast & Price Target

GH Research is poised for success with their treatment for Treatment-Resistant Depression, GH001, after receiving positive FDA feedback on CMC and their proprietary aerosol delivery device. With promising short-term and long-term efficacy results, strong financials and upcoming milestones such as FDA alignment on the Phase III pivotal design and global pivotal study initiation, GH Research is set to transform the lives of patients and provide significant returns for investors.

GH Research is facing multiple risks, including a potential deterioration in clinical profile during a Phase 3 study, potential delays due to FDA requirements for additional information and concerns around functional unbinding, and uncertainty surrounding the use of an inert placebo in their pivotal studies. The recent alignment of CMC and device plans indicates progress, however, the company's current engagement with the FDA and the possibility of needing to use an inert placebo raise concerns about potential delays and changes to the study design. Financially, GHRS disclosed an update to their 2Q26 earnings, with an increased probability of success to 55%.